The diagnosis of perinatal insults currently relies on adequate documentation of general medical and obstetric factors and on radiologic and laboratory assessments. The measurement of brain constituents such as S100B protein may offer an alternative and direct indicator of cell damage in the nervous system when clinical and radiologic assessments are still silent and has the additional advantage of providing a quantitative indicator of the extent of brain lesions. S100B protein has been measured by several immunoassays in biological fluids (i.e., cerebrospinal fluid, blood, amniotic fluid, and urine) from fetuses and newborns at high risk of perinatal brain damage. S100B protein in biological fluids increased at an early stage when standard monitoring procedures were still silent in the study populations that later developed brain damage. S100B concentration was also significantly correlated with the extent of brain lesions. S100B protein appears to satisfy the criteria for a marker for brain injuries in perinatal medicine: (a) simple to perform measurements with good reproducibility; (b) detection in a variety of biological fluids, possibly reducing perinatal stress related to testing; (c) possible use in longitudinal monitoring because of its 1-h half-life; and (d) well-established use as an early and quantitative marker of brain lesions/damage. Finally, because of the neurotrophic role putatively played by S100B, its measurement in biological fluids at pre-/ perinatal ages makes it a candidate for the laboratory evaluation of brain maturation.
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Epidemiology of Perinatal Brain Damage
Our knowledge of the timing of adverse insults is important in relation to future measures of prevention. However, such knowledge is still incomplete and under debate. For example, the reported contribution of asphyxia at birth to cerebral palsy in infants born at term varies from 8% to 28% (1) (2) (3) .
Preterm birth accounts for most cases of perinatal mortality and for ϳ40% of neurologically handicapped children. According to population studies by Hagberg et al. (4 ) , ϳ60% of neurologic handicaps in preterm infants are attributable to peri-/neonatal events, 10% are of antenatal origin, and 30% are of generally unknown origin. In infants born at term, 50% of cases of cerebral palsy have a prenatal etiology, 36% are of peri-/neonatal origin, and 14% of cases are of unknown etiology. Our understanding of the timing of insults and of contributing factors may be improved by adequate documentation of general medical and obstetric factors, determination of pH and blood gases in cord blood, and neonatal neuroimaging. Other diagnostic tools that may be of crucial importance are measurements of markers of perinatal brain injury in biological fluids. The key word is "prevention", with the aim of improving our ability to detect fetuses and newborns at risk of brain injury at an earlier stage, when the window for therapeutic action is still open. Both pre-and postnatal interventions show considerable promise: antenatal administration of glucocorticoids, the optimal management of labor and delivery, and the postnatal stabilization of critical newborns seem to dramatically improve the quality of life of these individuals. Significant decreases in the rate of cerebral bleeding and of adverse long-term neurologic outcome have been shown (5) (6) (7) (8) . On the other hand, the same findings support the need for additional markers to optimize the timing of treatment and, at the same time, to monitor their true effectiveness.
The possibility of longitudinal monitoring of the effects of drugs and supportive care is second in importance only to prevention as a means to minimize brain trauma and the numbers of neurologically handicapped children.
Standard Diagnostic Procedures for Early Detection of Perinatal Brain Damage
The essential steps for establishing a diagnosis of cerebral bleeding or of hypoxic ischemic events, the main factors involved in the genesis of perinatal brain damage in preterm and term infants, are similar. They are based on clinical examination, continuous electroencephalographic monitoring, cerebral ultrasound and Doppler velocimetry recordings, cerebrospinal fluid (CSF) 3 assessment, cerebral computerized tomography, magnetic resonance imaging, and proton magnetic resonance spectroscopy (5, 6 ) . These tools can provide useful and crucial information regarding the presence, location, and extent of brain injury and may be useful in establishing a prognosis. Although there is a wide range of diagnostic possibilities, there are several problems associated with the early diagnosis of cases at risk. The limited interval for diagnosis and therapeutic intervention and the confusing/ambiguous effects of sedative and anticonvulsant drugs are the main factors involved. This particularly applies to neurologic examination (5, 6 ) , electroencephalography (9 ) , and cerebrovascular recordings (10 -12 ) . Other limitations are poor reproducibility and the need for complex measurements (CSF measurements), infrequent use of longitudinal monitoring, and high costs (computerized tomography, magnetic resonance imaging, and proton magnetic resonance spectroscopy). For these reasons, cerebral ultrasound scanning is the procedure of choice for diagnosis, although the progression and extent of hemorrhage and brain insults can be defined only at a later stage (i.e., after more than 6 -12 h), which limits the possibility of intervention (5, 6 ) . In this respect, therapeutic procedures that aim to maintain adequate cerebrovascular perfusion and new approaches, such as selective head cooling with or without moderate hypothermia, have been shown to improve the outcome for these infants (6 ) . Nevertheless, the need for additional markers that enable longitudinal monitoring and that assess the effectiveness of these interventions is justified. S100B Protein: Biochemical, Biological, and Pathophysiologic Features
The term S100B refers to members of a multigenic family of calcium-modulated proteins (S100 proteins), mostly of low molecular mass (ϳ10 000 Da), that were first identified (on the basis of methods available at the time) as a protein fraction detectable in brain but not in nonneural extracts and called S100 because of their solubility in a 100%-saturated solution with ammonium sulfate (13 ) . At present, at least 20 proteins have been identified as belonging to the S100 protein family, the members of which are characterized by the presence of a pair of so-called EF-hand (i.e., helix-loop-helix) calcium-binding motifs (14 ) , first discovered in the crystal structure of parvalbumin (15 ) , that induce conformational changes of the protein after binding to calcium (16, 17 ) . This conformational change may facilitate the interaction of S100 proteins with a secondary effector: S100 proteins are generally thought to be calcium sensor proteins that modulate biological activity via calcium binding (18 ) . In addition, some S100 members have been shown to bind Zn 2ϩ and Cu 2ϩ (19, 20 ) , suggesting the possibility that their biological activity in some cases might be regulated by Zn 2ϩ and/or Cu 2ϩ , rather than by Ca 2ϩ (21 ) . Interestingly, the S100 proteins are highly conserved in amino acid composition among vertebrate species (22 ) , and S100-like proteins have also been immunologically detected in planarians and spinach leaves (23, 24 ) . Most S100 proteins exist as dimers (frequently homodimers) within cells and are generally expressed and distributed in a cell-specific fashion, indicating a conserved biological role.
In particular, S100B, a homodimer of a subunit (␤ subunit) that constitutes the bulk of the fraction originally isolated from brain extracts, was regarded for more than a decade as specific to the nervous system. A later study showed that the protein was not restricted to the nervous system (25 ) . Since then, the location of S100B has been extensively studied in mammalian tissues, including human tissues (26 -30 ) . In the nervous system, the protein appears to be most abundant in glial cells, although its presence in neuronal subpopulations has also been reported (31, 32 ) . In nonneural tissues, it is distributed widely in definite cell types, including melanocytes, Langerhans cells, chondrocytes, folliculostellate cells of the adenohypophysis, adrenal gland satellite cells, Leydig cells, and interdigitating reticulum cells (27 ) , whereas adipose tissue constitutes a site of concentration for the protein comparable to the nervous tissue (33 ) .
The biological role of this protein within the cell populations that contain it has not been completely elucidated, although many hypotheses have been formulated, including the inhibition of protein phosphorylation (34 -38 ) , inhibition of cytoskeletal constituent assembly (39 -42 ) , stimulation of enzyme activities (43) (44) (45) (46) , and interaction with transcription factors (34, 47 ) . An extracellular biological role has also been hypothesized for S100B, which secreted by astrocytes as a cytokine could have a neurotrophic effect during both development and nerve regeneration at physiologic (nanomolar) concentrations, but at high (micromolar) concentrations could be neurotoxic, participating in the pathophysiology of neurodegenerative disorders (16 ) . In this respect, it could be relevant that S100B is coded on the long arm of chromosome 21 (21q22.3) (48 ), which is also involved in the translocation that causes Down syndrome. An increase in gene expression for the protein has also been related to the neurodegenerative processes associated with both Down syndrome and Alzheimer disease, on the basis of findings indicating that ␤-amyloid stimulates the synthesis of S100B, whereas ␤-amyloid precursor protein increases in cultures exposed to S100B (49, 50 ) . More generally, S100B could take part in inflammatory diseases that eventually lead to Alzheimer-like disorders, in which chronic gliosis occurs (51 ) . Interestingly, most studies of the extracellular function of S100B focus on the nervous system, whereas consistent hypotheses have not yet been formulated for a role of this protein in the extracellular environment in nonneural locations S100B in Biological Fluids as a Marker of Brain Damage S100B protein has been measured in several biological fluids (CSF, blood, urine, and amniotic fluid) by a series of immunoassays, which were indiscriminately used in various fluids. The earliest studies used immunoassays such as a microcomplement fixation assay, RIA, and a particlecounting immunoassay directly developed by the authors (52) (53) (54) (55) , whereas more recent studies have used very simple, sensitive, and inexpensive commercially available immunoassays such as a two-site IRMA (Sangtec), an immunoluminometric assay (Sangtec), and an ELISA (SynX Pharma). PCR has also been used to analyze S100B in blood and amniotic fluid (56 ) .
csf CSF was the first of various biological fluids in which the role of S100B as a marker of active brain damage was shown (52, 53 ) . Since then, several studies have been conducted, first in adults and later in children, and have established that high concentrations of the protein indicate the occurrence of brain injury such as neurodegenerative diseases, cerebral tumors, cerebral trauma, and cerebrovascular diseases (57, 58 ) . The finding of a rapid increase in CSF S100B after brain damage, such as traumatic or focal ischemic insult, has also been confirmed in animal models (59 ) . In perinatal medicine, measurements of S100B protein in CSF have been used to monitor infants affected by perinatal asphyxia and posthemorrhagic ventricular dilatation brain damage during cardiac surgery (60 -62 ) ( Table 1) . In this setting, S100B concentrations correlated with the extent of brain lesions, with long-term prognosis, and with neurologic impairment at 1 year of age or death before that time. The measurement of S100B concentrations in CSF has also been suggested as a tool to screen patients with the most pessimistic prognoses from neuroprotective trials. In this regard, the need to use age-matched reference values when evaluating S100B protein in neurologic diseases has been emphasized (63 ) .
It is also noteworthy that on the basis of CSF dynamics, a concentration gradient decreasing from ventricular and lumbar CSF (in contrast to blood-derived proteins) has also been shown (64 ) .
blood
Since the pioneering observations in CSF, which represents the biological fluid into which brain constituents might most directly be released during active brain damage, a series of studies have been performed to investigate the usefulness of measuring S100B in blood as an index of brain damage, given that blood is the most widely used fluid for laboratory tests. The studies were based on the hypothesis that during active brain injury at least some of the S100B released from the damaged tissue could spread into the systemic circulation (54 ), also as a result of hemodynamic rearrangement of the brain-blood barrier. S100B was measured mainly in the blood of patients affected by the above-mentioned diseases (see the section on CSF), to which was added malignant melanoma on the basis of the location of the protein in melanocytes (55, (65) (66) (67) (68) . Many of the studies focused on trauma, supporting the notion that high blood concentrations of S100B are an index of posttraumatic brain damage (69, 70 ) . Similar results were also obtained in rats after controlled cortical impact (71 ) . However, caution has recently been suggested in this respect because, even in the absence of head injury, trauma has been shown to lead to high serum concentrations of S100B, probably originating from adipose tissue, where the protein is highly concentrated (72 ) . This also applies when monitoring the occurrence of brain damage attributable to ischemia-reperfusion injury in patients subjected to open-heart surgery, in which thoracotomy can induce traumatic release of S100B from adipose tissue (73 ) . The latter studies suggest that nonacute S100B measurements may be of greater prognostic value than acute measurements. As for CSF, the first studies were performed in adult patients (73, 74 ) , later in children (75 ) , and finally in the perinatal period. At this stage, the usefulness of a marker able to detect the occurrence and the extent of brain lesions is particularly relevant because of the high mortality and morbidity rates in high-risk infants. In addition, the use of a brain constituent as a marker opened the possibility for a direct indication of brain damage when clinical and radiologic signs are still silent. Increased blood concentrations of S100B were in fact detected ϳ48 to 72 h before any clinical, laboratory, or ultrasound signs of cerebral bleeding in preterm infants [intraventricular hemorrhage (IVH)] (76 ) or of hypoxicischemic encephalopathy (HIE) in full-term infants (Table  1 ) (77, 78 ) . In the latter study, Nagdyman et al. (78 ) reported that S100B protein concentrations in cord blood were already significantly higher (range, 1.1-3.7 g/L) in asphyxiated full-term infants suffering from birth asphyxia and HIE.
The same authors performed longitudinal S100B protein monitoring in peripheral blood and demonstrated a peak concentration of the protein 6 h after birth (range, 2.5-52.3 g/L, according to the severity of HIE) with a progressive decrease in S100B at 24 h (range, 1.2-9.0 g/L). The positive predictive value of S100B for HIE with a protein cutoff of 8.5 g/L at 2 h from birth was 71%, the negative predictive value was 90%, the sensitivity was 71%, and the specificity was 90% (78 ) . S100B blood concentrations also correlated with abnormal cerebral hemodynamic patterns (increased cerebrovascular resistance) and with the extent of IVH both in preterm and in full-term asphyxiated infants (76, 77 ) .
In asphyxiated full-term infants, an early increase in S100B was found to be predictive of HIE and subsequent adverse neurologic outcomes (78 ) . Because ischemiareperfusion injury is known to be one of the major complications in newborn infants undergoing open-heart surgery, increased blood S100B has also been indicated as an index of brain injury attributable to surgical procedures (73, 75, 79 ) . Similarly, S100B protein has also been used to monitor the occurrence of cerebral complications in preterm and term infants undergoing extracorporeal membrane oxygenation support for treatment of respiratory distress (80, 81 ) . The usefulness of measuring S100B in the cord blood of high-risk pregnancies, such as intrauterine growth-retarded (IUGR) fetuses, in which increased S100B could indicate brain injury attributable to impaired feto-placental perfusion deserves attention (82, 83 ) . In particular, S100B concentrations have been shown to be higher (3.6 Ϯ 1.44 g/L) in IUGR fetuses with redistribution of fetal-placental blood flow, the socalled "brain sparing effect", and correlated with the degree of fetal hemodynamic impairment, as indicated by an altered middle cerebral artery Doppler pattern, whereas IUGR fetuses without "brain sparing effect" showed S100B concentrations similar (1.7 Ϯ 1.25 g/L) to those of non-IUGR fetuses (1.12 Ϯ 0.74 g/L) (82 ) . In this pathologic condition, disturbances in the organization of quiet or active fetal behavioral states, which are known to constitute echographic signs of brain injury (84, 85 ) , were also correlated with high cord blood S100B concentrations (86 ) . Cord blood S100B measurements were also used to assess the effects of vasodilation treatment with maternal NO administration in IUGR fetuses (87 ) . At present, data correlating S100B protein with clinical prenatal data, other fetal well-being tests, and maternal medical conditions (e.g., hypertension, insulin-dependent diabetes, and coagulopathies) are lacking: such data could be of use in investigating the role of S100B in fetomaternal diseases.
Finally, because the gene encoding for S100B is located on chromosome 21, higher concentrations of the protein have, not surprisingly, been found in the blood of fetuses with trisomy 21, although attempts to use measurements of S100B in maternal blood in screening for Down syndrome, which is potentially very interesting, were unsuccessful: no significant differences in concentrations between uncomplicated and trisomy 21 pregnancies were found (88, 89 ) . These results are probably attributable to the effects of protein dilution or to the inability of the protein to pass into the placenta because of its molecular mass.
urine
Although studies of S100B concentrations in CSF and blood as a pathologic marker have offered consistent and useful results, the potential for developing new areas of investigation in perinatal medicine and improving the care of newborns depends on meeting the requirements of longitudinal monitoring of high-risk patients for the possible occurrence of brain damage. This is particularly important because repeated blood sampling can induce anemia in premature infants (90 ) . The usefulness of frequent S100B measurements is supported by data on the kinetic properties of this protein, which has a half-life of ϳ1 h and is eliminated mainly by the kidneys (91 ) . For this reason, urine could constitute an excellent fluid for these studies. An initial report showed the presence of S100B in the urine of healthy preterm and term newborns and its correlation with gestational age at sampling, offering a normality reference curve (Table 1 ) (92 ) . Similar studies were subsequently performed on urine (93 ) on the basis of previous investigations of the blood of braindamaged preterm and term infants (76 -78 ) . The results indicated that urine S100B concentrations at birth were significantly higher in preterm newborns (2.51 Ϯ 0.79 g/L) who later developed cerebral bleeding and/or brain damage at a stage when all routine clinical, laboratory, and ultrasound investigations were still silent. Longitudinal monitoring of urine S100B concentrations showed a progressive increase in the concentration of the protein with a peak at 72 h from birth (10.51 Ϯ 3.21 g/L). The positive predictive value of S100B for IVH with a protein cutoff of 0.70 g/L at 2 h from birth was 80.5%, the negative predictive value was 100%, the sensitivity was 100%, and the specificity was 100%.
Future research protocols on S100B urinary patterns will probably provide a new and easier means of investigating pathophysiologic brain conditions (not only in the perinatal period), which have previously been studied by measuring the protein in CSF and blood, involving procedures that are more stressful for patients.
amniotic fluid
The search for a nervous system constituent, such as S100B, that could be used to detect prenatal brain pathologies in amniotic fluid is not new. In studies using a particle-counting immunoassay, the protein was shown to be present in the amniotic fluid of anencephalic and open spina bifida fetuses (94 ) as well as in cases of fetal death (95 ) . Normal amniotic fluid appeared to be devoid of the protein. More recent studies used a more sensitive radioimmunometric assay (limit of detection, 0.2 g/L vs 1.5 g/L) to propose a normality reference curve for S100B in amniotic fluid that appeared to be correlated with gestational age, opening intriguing prospects concerning the putative neurotrophic role of the protein (96 ) . In this respect, the recent finding of S100B in feto-placental tissues could be relevant (56 ) . However, the possibility of a placental contribution to S100B concentrations in fetal fluids, despite a lack of evidence at present, should be taken into consideration (97 ) .
The localization of the gene encoding for S100B on the long arm of chromosome 21, which is believed to be responsible for trisomy 21 (98 ) , stimulated studies on the use of S100B measurements in amniotic fluid as a diagnostic aid for Down syndrome. As expected, concentrations of the protein were ϳ1.5 times higher in trisomy 21 amniotic fluid (0.92 Ϯ 0.45 g/L) than in controls (0.52 Ϯ 0.24 g/L) (97) (98) (99) . However, as the difference in S100B concentrations is not sufficient to validate this test as a clear-cut screening tool and the relevant sampling procedures have no advantage over other, more specific methods (reverse transcription-PCR, fluorescence in situ hybridization), these results are of scientific rather than clinical diagnostic value.
Future Prospectives
The bulk of studies showing the usefulness of S100B as a marker of brain injury have to date referred to measurements in CSF and blood. However, considering the simple procedure involved in urine sampling, it is possible to predict an increase in interest concerning the investigation of S100B in this biological fluid, which at present can be regarded only as a promising field of research. Likewise, the restricted number of studies on amniotic fluid at present offers poor information on fetal brain injury. Nevertheless, because amniotic fluid potentially offers the possibility of monitoring prenatal life, measurement of S100B in amniotic fluid remains a candidate method for the detection of fetal brain injury and/or fetal death.
Another potential use of S100B measurements in biological fluids is to monitor the effectiveness of therapeutic intervention in high-risk term and preterm infants, as has already been reported in IUGR fetuses treated with NO (87 ) .
Of the numerous functions attributed to the S100B protein, a neurotrophic role appears to be particularly intriguing in relation to perinatal medicine. After early observations in healthy fetuses by Zuckerman et al. (100 ) showing that the caudo-rostral pattern of accumulation of S100 parallels the biochemical, morphologic, and electrophysiologic maturation of the nervous system, attention has more recently focused on the possibility that information concerning the role of this protein could be obtained by studying the pattern of S100B concentrations in different biological fluids in the prenatal and perinatal periods. In the second trimester of pregnancy, when S100B is known to increase progressively in the brain cortex (101 ), a parallel increase at the same gestational age has been shown in the amniotic fluid of uncomplicated pregnancies. The amniotic fluid concentration of S100B not only correlated with gestational age, but also with echographic findings suggestive of brain development.
A pattern of S100B concentrations suggestive of a role in brain maturation processes has also been shown in cord blood in the third trimester of pregnancy, when a progressive decrease of the protein is observed, possibly reflecting reduced release of the trophic factor at a later stage of fetal-neonatal brain maturation. The same pattern was observed in urine collected immediately after birth from healthy preterm and term newborns.
Finally, we recently found high concentrations of S100B (80 -100 times higher than in other biological fluids) in human milk (unpublished data), which may hypothetically constitute an exogenous source of the trophic factor in early brain developmental stages. On the other hand, to date there are no data on the absorption of S100B in maternal milk by infants and, therefore, on the effect of a potential contribution of exogenous S100B to measurements of the protein in the biological fluids of infants.
In conclusion, taken together, the above findings could open the way to additional studies aimed at investigating a potential use of S100B measurements in perinatal medicine and in pediatric patients as a monitoring tool for brain development.
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